Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory…

Principal Investigator: Wang, Eunice S

A FIRST-IN-HUMAN, PHASE 1, DOSE ESCALATION STUDY OF SGR-2921 AS MONOTHERAPY IN SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME

Principal Investigator: Wang, Eunice S

(AALL1732) A Phase 3 Randomized Trial of Inotuzumab Ozogamicin(IND#:133494, NSC#:772518)for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-InductionTherapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Principal Investigator: Twist, Clare J

Asciminib as Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia who do not Achieve a Deep Molecular Remission (ALERT CML)

Principal Investigator: Thompson, J

A first-in-human (FIH), phase 1, multicenter, open- label, dose escalation and expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally administered GLB-001 in patients with relapsed or refractory…

Principal Investigator: Wang, Eunice S

Phase 1/1b Trial of Talazoparib and Gemtuzumab ozogamicin in Adult Patients with Relapsed and/or Refractory Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia

Principal Investigator: Wang, Eunice S

A Phase II Study of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia

Principal Investigator: Green, Steven D

An Open-Label Phase 1A/1B Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPa-Fc-CD40L) in Combination With Azacitidine or with Azacitidine and Venetoclax for the Treatment of Subjects With Higher Risk Myelodysplastic Syndrome (MDS) or Acute…

Principal Investigator: Green, Steven D

Phase I, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with…

Principal Investigator: Wang, Eunice S

A bilingual virtually-based intervention (PEDALL) for the prevention of weight gain in childhood ALL patients considering key genetic and sociodemographic risk factors

Principal Investigator: Kelly, Kara M

A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Principal Investigator: Wang, Eunice S

2215-CL-0203 A Phase 1/2, Multicenter, Open-Label, Randomized, Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for…

Principal Investigator: Wang, Eunice S

A Phase 1 Study of ASCIMINIB in combination with dasatinib, prednisone, and blinatumomab in patients with BCR-ABL1 positive (BCR-ABL1+) B-cell acute lymphoblastic leukemia (B-ALL) and chronic myeloid leukemia (CML)

Principal Investigator: Wang, Eunice S

A PHASE 1, OPEN-LABEL, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF NC525 IN SUBJECTS WITH ADVANCED MYELOID NEOPLASMS

Principal Investigator: Griffiths, Elizabeth A

A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia

Principal Investigator: Griffiths, Elizabeth A

Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who are Ineligible for Standard Induction Therapy

Principal Investigator: Wang, Eunice S

(ASCT2031) A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or…

Principal Investigator: Twist, Clare J

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation

Principal Investigator: Wang, Eunice S

A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies

Principal Investigator: McCarthy, Philip L

A Phase Ib/2 study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positve Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Principal Investigator: Thompson, J

AALL1631 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

Principal Investigator: Twist, Clare J

(ARO-013) Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects = 75 Years of Age with Relapsed/Refractory FLT3 Mutated…

Principal Investigator: Wang, Eunice S